4/A: Theravance Biopharma Director Amends Share Sale

Theravance Biopharma Director Eran Broshy filed an amended Form 4 to correct the number of shares sold on November 11, 2025, under a Rule 10b5-1 trading plan.

Summary

• An amendment to a previously filed Form 4 was submitted to correct an administrative error regarding the number of Ordinary Shares sold at $18.50 on November 11, 2025.
• The originally reported amount of 29,500 shares sold at $18.50 was incorrect; the corrected amount is 15,500 shares.
• Eran Broshy, a Director of Theravance Biopharma, Inc., engaged in multiple transactions on November 11, 2025.
• Sold 15,500 Ordinary Shares at a price of $18.50 per share.
• Sold an additional 15,500 Ordinary Shares at a price of $17.00 per share.
• Exercised stock options to acquire 14,000 Ordinary Shares at an exercise price of $10.15 and subsequently sold all these shares on the same day at $18.50 per share.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2024.
• Following these transactions, beneficial ownership of Ordinary Shares is 60,204, and beneficial ownership of Share Options is 107,878.

Sentiment

Score: 5

Explanation: The filing is neutral in terms of company performance, primarily an administrative correction of an insider transaction. While insider selling can be perceived as slightly negative, the pre-planned nature via a 10b5-1 plan mitigates this, and the correction itself is a positive for transparency.

Positives

• The filing corrects an administrative error, ensuring accuracy and transparency in public disclosures.
• All reported transactions were pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to share disposition rather than reactive selling.

Negatives

• Director Eran Broshy sold a significant number of Ordinary Shares (totaling 45,000 shares across various transactions) on November 11, 2025.

Future Outlook

N/A

Management Comments

• Transactions were effected pursuant to the reporting person's Rule 10b5-1 trading plan adopted on March 14, 2024.

Industry Context

N/A

Stakeholder Impact

• Shareholders: The correction ensures accurate public records of director shareholdings and transactions, which is beneficial for transparency. The underlying insider selling, even if planned, might be viewed with slight caution by some investors.

Key Dates

Recommendation

The filing is an amendment to correct an administrative error in a director's previously reported share sales. While insider selling, even under a 10b5-1 plan, can be perceived negatively, this specific filing primarily addresses a data correction and does not provide new fundamental information about the company's performance or outlook. Therefore, it does not warrant a change in investment recommendation based solely on this amendment.

Keywords

Theravance Biopharma, TBPH, Form 4/A, Insider Trading, Share Sale, Director, Stock Options, 10b5-1 Plan, Amendment